Table 3.

Future anti-angiogenic targets to consider

Drug target	Relevant literature/studies
HIF-1/2	Subhani S, et al. Angiogenesis. 2016 Jul;19(3):257–73.
Angiopoietin-like 4 (ANGPTL4)	Babapoor-Farrokhran S, et al. Proc Natl Acad Sci U S A. 2015;112(23):E3030-E3039. Xin X, et al. Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):E3425–34. Kwon SH, et al. Ophthalmology. 2015 May;122(5):968–75.
Stromal-derived factor-1 (SDF-1) and its receptor CXCR4	Ghanem I, et al. Am J Transl Res. 2014 Jul 18;6(4):340–52.
Metabolic gene products	Treps L, et al. Pharmacol Rev. 2016 Jul;68(3):872–87.
Matrix metalloproteinases (MMP)	Sampieri CL, et al. J Cancer Res Ther. 2013 Jul-Sep;9(3):356–63. Zhang X, et al. Int J Oncol. 2016 May;48(5):1783–93. Chang JH, et al. Surv Ophthalmol. 2016 Jul-Aug;61(4):478–97.
Inflammation and inflammatory cytokines	de Oliveira Dias JR, et al. Br J Ophthalmol. 2011 Dec;95(12):1631–7. Schor AM, Schor SL. Eye (Lond). 2010 Mar;24(3):450–8.
Reactive oxygen species (ROS)	Wilkinson-Berka JL, et al. Clin Sci (Lond). 2013 May;124(10):597–615.
Stem cell and endothelial progenitor therapy	Nazari H, et al. Prog Retin Eye Res. 2015 Sep;48:1–39.
Integrin antagonists	Salehi-Had H, et al. PLoS One. 2011 Apr 29;6(4):e18864. Varner JA, et al. Important Adv Oncol. 1996:69–87. Tolentino MJ. Curr Mol Med. 2009 Nov;9(8):973–81.
Methionine aminopeptidase	Ma AC, et al. Blood. 2011 Nov 17;118(20):5448–57. Mauriz JL, et al. Curr Drug Targets. 2010 Nov;11(11):1439–57.